Mouse monoclonal antibody

Anti-Complement component C3a/C3a(desArg)/C3 (human

CAT NO: GAU 017-01 | Application: ELISA, WB

Request Price
×

Request Price

"*" indicates required fields

Name*
Consent*
This field is for validation purposes and should be left unchanged.

Product Summary

Cat. No.
GAU 017-01
Specificity
Recognizes an epitope that is present on human C3, C3a and C3a (desArg). Does not cross-react with C4a or C5a.
Immunogen
Human C3a
Host
Mouse
Positive Species Reactivity
Human
Negative Species Reactivity
Not determined
Isotype
IgG1/k
Gene ID
718
Clone Number
D17/1
Epitope Specificity
GAU 017-01 recognizes different epitopes on the 9 kDa C3a than GAU 013-16. No reaction is seen with a synthetic octapeptide representing the C3a C-terminal.
Unit Size
400 µL: Cat. No. GAU 017-01-04 1 mL: Cat. No. GAU 017-01-1 1 mg/mL +/- 15%. See Certificate of Analysis for details.
Purification
Protein A/G purified (from culture supernatant)
Form
Liquid
Solvent
0.01 M phosphate buffer, pH 7.4, containing 0.5 M NaCl and 15 mM sodium azide
Conjugation
Unconjugated BSA free
Storage
4-8ºC without exposure to light. No precautions necessary during handling.
Target
Complement C3a is an anaphylatoxin of 77 amino acid residues released by the action of the C3 convertases on the N-terminal of the alpha chain of C3. It is rapidly inactivated by serum carboxypeptidase N which removes the C-terminal arginine residue generating C3a (desArg).

Application

ELISA: GAU 017-01 can be used as a biotinylated detection antibody in sandwich ELISA with GAU 013-16 capture antibody (1-5). Does not inhibit the biological activity of C3a. (1)

WB: GAU 017-01 can be used in Western blotting. (1, 4, 5)

Scientific References

1. Nezlin R, Freywald A, Oppermann M (1993) Proteins separated from human IgG molecules. Mol. Immunol. 30:935-940.

2. Oppermann M, Liebmann F, Götze O. (1987) Purification and quantification of human C3a anaphylatoxin using monoclonal antibodies. Complement 4:205-206

3. Oppermann M, Haubitz M, Quintin E, Götze O (1988) Complement activation in patients with renal failure as detected through the quantitation of fragments of the complement proteins C3, C5, and Factor B. Klin Wochenschr 66:857-864.

4. Puschel GP, Oppermann M, Muschol W, Gotze O, Jungermann K. (1989) Increase of glucose and lactate output and decrease of flow by human anaphylatoxin C3a but not C5a in perfused rat liver. FEBS Lett. 16;243(1):83-7.

5. Negishi A, Ono M, Handa Y, Kato H, Yamashita K, Honda K, Shitashige M, Satow R, Sakuma T, Kuwabara H, Omura K, Hirohashi S, Yamada T (2009) Large-scale quantitative clinical proteomics by label free liquid chromatography and mass spectrometry. Cancer Sci 100:514-519.

Cat. No.
GAU 017-01
Specificity
Recognizes an epitope that is present on human C3, C3a and C3a (desArg). Does not cross-react with C4a or C5a.
Immunogen
Human C3a
Host
Mouse
Positive Species Reactivity
Human
Negative Species Reactivity
Not determined
Isotype
IgG1/k
Gene ID
718
Clone Number
D17/1
Epitope Specificity
GAU 017-01 recognizes different epitopes on the 9 kDa C3a than GAU 013-16. No reaction is seen with a synthetic octapeptide representing the C3a C-terminal.
Unit Size
400 µL: Cat. No. GAU 017-01-04 1 mL: Cat. No. GAU 017-01-1 1 mg/mL +/- 15%. See Certificate of Analysis for details.
Purification
Protein A/G purified (from culture supernatant)
Form
Liquid
Solvent
0.01 M phosphate buffer, pH 7.4, containing 0.5 M NaCl and 15 mM sodium azide
Conjugation
Unconjugated BSA free
Storage
4-8ºC without exposure to light. No precautions necessary during handling.
Target
Complement C3a is an anaphylatoxin of 77 amino acid residues released by the action of the C3 convertases on the N-terminal of the alpha chain of C3. It is rapidly inactivated by serum carboxypeptidase N which removes the C-terminal arginine residue generating C3a (desArg).

ELISA: GAU 017-01 can be used as a biotinylated detection antibody in sandwich ELISA with GAU 013-16 capture antibody (1-5). Does not inhibit the biological activity of C3a. (1)

WB: GAU 017-01 can be used in Western blotting. (1, 4, 5)

1. Nezlin R, Freywald A, Oppermann M (1993) Proteins separated from human IgG molecules. Mol. Immunol. 30:935-940.

2. Oppermann M, Liebmann F, Götze O. (1987) Purification and quantification of human C3a anaphylatoxin using monoclonal antibodies. Complement 4:205-206

3. Oppermann M, Haubitz M, Quintin E, Götze O (1988) Complement activation in patients with renal failure as detected through the quantitation of fragments of the complement proteins C3, C5, and Factor B. Klin Wochenschr 66:857-864.

4. Puschel GP, Oppermann M, Muschol W, Gotze O, Jungermann K. (1989) Increase of glucose and lactate output and decrease of flow by human anaphylatoxin C3a but not C5a in perfused rat liver. FEBS Lett. 16;243(1):83-7.

5. Negishi A, Ono M, Handa Y, Kato H, Yamashita K, Honda K, Shitashige M, Satow R, Sakuma T, Kuwabara H, Omura K, Hirohashi S, Yamada T (2009) Large-scale quantitative clinical proteomics by label free liquid chromatography and mass spectrometry. Cancer Sci 100:514-519.

Downloads

+

Product Specification

Non-hazardous statement (SDS)

Related Products

+

>

Anti-Complement component C3a/C3a/(desArg)/C3 (human

CAT. NO. GAU 013-16

>

Anti-Complement component C3a/C3a(desArg)/C3 (human)

CAT. NO. GAU 017-01B

×